share_log

Immatics Biotechnologies GmbH (NASDAQ:IMTXW) Sees Large Increase in Short Interest

Defense World ·  Apr 23, 2023 15:12

immatics biotechnologies GmbH (NASDAQ:IMTXW – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 17,400 shares, a growth of 6.1% from the March 15th total of 16,400 shares. Based on an average daily trading volume, of 5,900 shares, the days-to-cover ratio is presently 2.9 days.

immatics biotechnologies Price Performance

Shares of IMTXW stock opened at $1.53 on Friday. immatics biotechnologies has a twelve month low of $0.88 and a twelve month high of $4.41. The stock has a fifty day moving average price of $1.80.

Get immatics biotechnologies alerts:

Institutional Investors Weigh In On immatics biotechnologies

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of immatics biotechnologies during the 4th quarter worth $28,000. Jefferies Financial Group Inc. purchased a new stake in shares of immatics biotechnologies during the 4th quarter worth $80,000. Alyeska Investment Group L.P. purchased a new stake in shares of immatics biotechnologies during the 4th quarter worth $529,000. Finally, Aristeia Capital LLC lifted its stake in shares of immatics biotechnologies by 3,293.6% during the 4th quarter. Aristeia Capital LLC now owns 754,590 shares of the company's stock worth $1,856,000 after purchasing an additional 732,354 shares during the last quarter.

See Also

  • Get a free copy of the StockNews.com research report on immatics biotechnologies (IMTXW)
  • MarketBeat Week in Review – 4/17 – 4/21
  • 2 Industrial Strength Dividend Stocks Melting Up
  • Proctor & Gamble Is Going To Set A New High
  • AutoNation's Plans are Keeping Analysts Around
  • Netflix Increases Buybacks: Can It Complete A Reversal In 2023?

Receive News & Ratings for immatics biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for immatics biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment